Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Biogen Inc. NASDAQ: BIIB. In a filing disclosed on March 27th, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on February 25th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.
Representative Robert Bresnahan, Jr. also recently made the following trade(s):
- Purchased $1,001 - $15,000 in shares of Intuit NASDAQ: INTU on 3/7/2025.
- Sold $1,001 - $15,000 in shares of Tesla NASDAQ: TSLA on 3/6/2025.
- Purchased $1,001 - $15,000 in shares of SEA NYSE: SE on 3/5/2025.
- Sold $1,001 - $15,000 in shares of Credo Technology Group NASDAQ: CRDO on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Meta Platforms NASDAQ: META on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Twilio NYSE: TWLO on 3/4/2025.
- Sold $15,001 - $50,000 in shares of Alibaba Group NYSE: BABA on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Zoom Video Communications NASDAQ: ZM on 3/4/2025.
- Purchased $1,001 - $15,000 in shares of Intel NASDAQ: INTC on 3/3/2025.
- Purchased $1,001 - $15,000 in shares of Snowflake NYSE: SNOW on 3/3/2025.
Biogen Stock Performance
Shares of BIIB stock traded down $0.88 during midday trading on Wednesday, hitting $131.15. 1,092,523 shares of the company were exchanged, compared to its average volume of 1,561,124. The firm has a market capitalization of $19.20 billion, a P/E ratio of 11.72, a PEG ratio of 1.51 and a beta of 0.01. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.90 and a current ratio of 1.35. Biogen Inc. has a 52 week low of $128.51 and a 52 week high of $238.00. The firm's 50 day moving average price is $141.63 and its two-hundred day moving average price is $158.82.
Biogen (NASDAQ:BIIB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, equities research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the business. Inspire Trust Co. N.A. increased its position in Biogen by 58.5% in the 3rd quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company's stock valued at $2,113,000 after acquiring an additional 4,025 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Biogen by 0.3% in the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company's stock worth $6,646,000 after purchasing an additional 111 shares during the last quarter. Centre Asset Management LLC increased its holdings in Biogen by 7.7% in the fourth quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company's stock valued at $7,880,000 after purchasing an additional 3,698 shares during the period. Amundi raised its position in Biogen by 35.6% during the 4th quarter. Amundi now owns 1,216,990 shares of the biotechnology company's stock worth $183,461,000 after purchasing an additional 319,478 shares during the last quarter. Finally, Nordea Investment Management AB lifted its holdings in Biogen by 48.0% during the 4th quarter. Nordea Investment Management AB now owns 117,963 shares of the biotechnology company's stock worth $17,901,000 after buying an additional 38,283 shares during the period. Institutional investors own 87.93% of the company's stock.
Analyst Ratings Changes
Several research analysts have weighed in on BIIB shares. StockNews.com cut Biogen from a "strong-buy" rating to a "buy" rating in a research report on Saturday, December 28th. Stifel Nicolaus lowered shares of Biogen from a "buy" rating to a "hold" rating and set a $175.00 price target on the stock. in a research report on Monday, December 16th. Royal Bank of Canada cut their price objective on shares of Biogen from $231.00 to $225.00 and set an "outperform" rating for the company in a report on Thursday, February 13th. Bank Of America (Bofa) lowered their target price on shares of Biogen from $178.00 to $163.00 and set a "neutral" rating on the stock in a report on Tuesday, February 11th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Biogen in a research report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $213.33.
Get Our Latest Analysis on Biogen
Insider Buying and Selling at Biogen
In other news, Director Stephen A. Sherwin sold 8,760 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now owns 11,318 shares in the company, valued at approximately $1,697,926.36. The trade was a 43.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company's stock.
About Representative Bresnahan
Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election.
Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.
About Biogen
(
Get Free Report)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Featured Stories
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
